SK284442B6 - Použitie steroidných antagonistov estrogénových receptorov na antikoncepciu pre mužov - Google Patents
Použitie steroidných antagonistov estrogénových receptorov na antikoncepciu pre mužov Download PDFInfo
- Publication number
- SK284442B6 SK284442B6 SK1238-97A SK123897A SK284442B6 SK 284442 B6 SK284442 B6 SK 284442B6 SK 123897 A SK123897 A SK 123897A SK 284442 B6 SK284442 B6 SK 284442B6
- Authority
- SK
- Slovakia
- Prior art keywords
- estrogen receptor
- tablet
- receptor antagonists
- antiestrogens
- male
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Materials For Medical Uses (AREA)
- Junction Field-Effect Transistors (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19510862A DE19510862A1 (de) | 1995-03-16 | 1995-03-16 | Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle |
PCT/EP1996/001191 WO1996028154A2 (fr) | 1995-03-16 | 1996-03-15 | Utilisation d'anti-oestrogenes comme contraceptifs masculins |
Publications (2)
Publication Number | Publication Date |
---|---|
SK123897A3 SK123897A3 (en) | 1998-02-04 |
SK284442B6 true SK284442B6 (sk) | 2005-04-01 |
Family
ID=7757669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1238-97A SK284442B6 (sk) | 1995-03-16 | 1996-03-15 | Použitie steroidných antagonistov estrogénových receptorov na antikoncepciu pre mužov |
Country Status (21)
Country | Link |
---|---|
US (1) | US20010056086A1 (fr) |
EP (1) | EP0814803B1 (fr) |
JP (1) | JPH11501648A (fr) |
KR (1) | KR19980703057A (fr) |
CN (1) | CN1151792C (fr) |
AT (1) | ATE342055T1 (fr) |
CA (1) | CA2215373A1 (fr) |
CZ (1) | CZ293771B6 (fr) |
DE (2) | DE19510862A1 (fr) |
DK (1) | DK0814803T3 (fr) |
ES (1) | ES2275273T3 (fr) |
HU (1) | HUP9900313A3 (fr) |
IL (1) | IL117515A (fr) |
NO (1) | NO974256L (fr) |
NZ (1) | NZ303672A (fr) |
PL (1) | PL186085B1 (fr) |
PT (1) | PT814803E (fr) |
SK (1) | SK284442B6 (fr) |
TW (1) | TW503106B (fr) |
WO (1) | WO1996028154A2 (fr) |
ZA (1) | ZA962176B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4344462C2 (de) | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
DE10159217A1 (de) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
EP2258375A1 (fr) | 2009-06-04 | 2010-12-08 | Bayer Schering Pharma Aktiengesellschaft | 17B-alkyl-17alpha-oxy-estratriene |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3213328A1 (de) * | 1982-04-06 | 1983-10-06 | Schering Ag | 3,4,17-trioxygenierte 4,9(11)-androstadiene |
GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
US5166201A (en) * | 1990-11-30 | 1992-11-24 | Merrell Dow Pharmaceuticals Inc. | 2β,19-ethylene bridged steroids as aromatase inhibitors |
FR2685332A1 (fr) * | 1991-12-20 | 1993-06-25 | Roussel Uclaf | Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments. |
-
1995
- 1995-03-16 DE DE19510862A patent/DE19510862A1/de not_active Withdrawn
-
1996
- 1996-03-15 DK DK96906768T patent/DK0814803T3/da active
- 1996-03-15 US US08/913,304 patent/US20010056086A1/en not_active Abandoned
- 1996-03-15 ES ES96906768T patent/ES2275273T3/es not_active Expired - Lifetime
- 1996-03-15 DE DE59611391T patent/DE59611391D1/de not_active Expired - Fee Related
- 1996-03-15 CZ CZ19972852A patent/CZ293771B6/cs not_active IP Right Cessation
- 1996-03-15 CA CA002215373A patent/CA2215373A1/fr not_active Abandoned
- 1996-03-15 EP EP96906768A patent/EP0814803B1/fr not_active Expired - Lifetime
- 1996-03-15 HU HU9900313A patent/HUP9900313A3/hu unknown
- 1996-03-15 PT PT96906768T patent/PT814803E/pt unknown
- 1996-03-15 KR KR1019970706466A patent/KR19980703057A/ko not_active Application Discontinuation
- 1996-03-15 WO PCT/EP1996/001191 patent/WO1996028154A2/fr active IP Right Grant
- 1996-03-15 JP JP8527294A patent/JPH11501648A/ja not_active Withdrawn
- 1996-03-15 SK SK1238-97A patent/SK284442B6/sk unknown
- 1996-03-15 CN CNB961926147A patent/CN1151792C/zh not_active Expired - Fee Related
- 1996-03-15 AT AT96906768T patent/ATE342055T1/de not_active IP Right Cessation
- 1996-03-17 IL IL11751596A patent/IL117515A/xx active IP Right Grant
- 1996-03-18 ZA ZA962176A patent/ZA962176B/xx unknown
- 1996-05-17 TW TW085105880A patent/TW503106B/zh not_active IP Right Cessation
-
1997
- 1997-09-15 NO NO974256A patent/NO974256L/no not_active Application Discontinuation
- 1997-09-16 PL PL96322253A patent/PL186085B1/pl not_active IP Right Cessation
- 1997-09-16 NZ NZ303672A patent/NZ303672A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL117515A0 (en) | 1996-07-23 |
CZ293771B6 (cs) | 2004-07-14 |
WO1996028154A2 (fr) | 1996-09-19 |
NO974256L (no) | 1997-11-14 |
WO1996028154A3 (fr) | 1997-05-01 |
CN1151792C (zh) | 2004-06-02 |
PL322253A1 (en) | 1998-01-19 |
PT814803E (pt) | 2007-02-28 |
DE19510862A1 (de) | 1996-09-19 |
NZ303672A (en) | 2000-07-28 |
MX9707008A (es) | 1997-11-29 |
KR19980703057A (ko) | 1998-09-05 |
ES2275273T3 (es) | 2007-06-01 |
IL117515A (en) | 2003-07-31 |
EP0814803B1 (fr) | 2006-10-11 |
DK0814803T3 (da) | 2007-02-19 |
HUP9900313A1 (hu) | 1999-06-28 |
CN1178463A (zh) | 1998-04-08 |
DE59611391D1 (de) | 2006-11-23 |
SK123897A3 (en) | 1998-02-04 |
CZ285297A3 (en) | 1997-12-17 |
JPH11501648A (ja) | 1999-02-09 |
TW503106B (en) | 2002-09-21 |
US20010056086A1 (en) | 2001-12-27 |
HUP9900313A3 (en) | 1999-11-29 |
PL186085B1 (pl) | 2003-10-31 |
NO974256D0 (no) | 1997-09-15 |
AU5004696A (en) | 1996-10-02 |
EP0814803A2 (fr) | 1998-01-07 |
AU713467B2 (en) | 1999-12-02 |
CA2215373A1 (fr) | 1996-09-19 |
ATE342055T1 (de) | 2006-11-15 |
ZA962176B (en) | 1996-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2174327C (fr) | Combinaison d'antagonistes de la progesterone et d'anti-oestrogenes a action partiellement agoniste pour l'hormonotherapie substitutive des femmes peri et postmenopausees | |
CA1330039C (fr) | Composes ayant des activites anti-progestatives et anti-oestrogeniques pour le traitement de tumeurs hormonodependantes | |
US6362237B1 (en) | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception | |
US20120225853A1 (en) | Hormone replacement therapy and depression | |
WO2010054758A1 (fr) | Combinaison pharmaceutique synergique contenant un antagoniste du récepteur des oestrogènes et une progestine | |
Donath et al. | Effects of partial versus pure antiestrogens on ovulation and the pituitary–ovarian axis in the rat | |
SK284442B6 (sk) | Použitie steroidných antagonistov estrogénových receptorov na antikoncepciu pre mužov | |
KR100729311B1 (ko) | 호르몬 대체 요법(hrt)용 조성물의 성분으로서의메조프로게스틴 (프로게스테론 수용체 조절물질) | |
DE4329344A1 (de) | Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri | |
MXPA97007008A (en) | Use of anti-estrogens for natural control in homb | |
Snyder et al. | Effect of epostane, ZK 98299, and ZK 98734 on the interruption of pregnancy in the rat |